staging and risk assessment
Since treatment depends substantially on the stage of the disease, initial staging should be thorough particularly in the small proportion of patients with early stages I and II (15-20%). Initial work-up should include a CT scan of the thorax, abdomen and pelvis, and a bone marrow aspirate and biopsy [IV, C] . An additional PET is not recommended according to the updated consensus. A complete blood count, routine blood chemistry including lactate dehydrogenase (LDH) and uric acid as well as screening tests for HIV and hepatitis B and C are required. The staging is given according to the Ann Arbor system with mention of bulky disease. For prognostic purposes, a Follicular Lymphoma-specific International Prognostic Index (FLIPI: more involved nodal sites, elevated LDH, age >60 years, advanced stage III/IV, hemoglobulin <12 g/dl) should be determined [I, A]. Stage III-IV consolidation. Meta-analysis suggests a limited benefit of interferon-a maintenance therapy, which has to be balanced against toxicity.
Rituximab maintenance remains investigational in first-line therapy. Myeloablative radiochemotherapy followed by autologous stem-cell transplantation prolongs progression-free survival but remains investigational in first-line therapy [I, A].
relapsed disease
A repeat biopsy is strongly recommended to rule out a secondary transformation into aggressive lymphoma. Selection of salvage treatment depends on efficacy of prior regimens. In early relapses (<12 months), a non-crossresistant scheme should be preferred (e.g. fludarabine after CHOP). Rituximab should be added if the previous antibodycontaining scheme achieved a >6-12 months duration of remission [IV] . Rituximab maintenance has a favorable side-effect profile and substantially prolongs progression-free survival with a strong tendency towards improved overall survival in relapsed disease even after antibody-containing induction [I, A]. Myeloablative consolidation followed by autologous stem-cell transplantation prolongs progression-free and overall survival but its role has to be redefined in the rituximab aera [I, B]. Radioimmunotherapy (preferable as consolidation) and potentially curative allogeneic stem-cell transplantation (optionally with dose-reduced conditioning) may be discussed in relapsed disease.
response evaluation
Adequate radiological tests should be performed mid-term and after completion of chemotherapy. Patients with insufficient or lack of response should be evaluated for early salvage regimens.
follow-up
History and physical examination every 3 months for 2 years, every 4-6 months for 3 additional years and subsequently once a year with special attention to transformation and secondary malignancies including secondary leukemia [V, D] . 
